Drug Profile

Tetrahydrocurcumin - Renibus Therapeutics

Alternative Names: RBT-2; Tetrahydrodiferuloylmethane - Renibus Therapeutics

Latest Information Update: 28 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Renibus Therapeutics
Class Anti-inflammatories; Antifibrotics; Catechols; Ketones; Small molecules
Mechanism of Action Antioxidants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Renal failure

Most Recent Events

28 Jul 2024 No recent reports of development identified for preclinical development in Renal-failure in USA
05 Jan 2023 Renibus Therapeutics plans to complete IND enabling studies to begin clinical development by 2023
05 Jan 2023 Renibus Therapeutics plans a phase I trial for Renal failure in 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com